Quark, Nitto Denko collaborate on fibrotic diseases

Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA therapeutics to treat fibrotic diseases. Quark will provide the RNAi technology and Nitto Denko will work on drug delivery. The two companies are aiming for an Investigational New Drug designation by the FDA by early 2012. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.